bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair

by Maria Zannes | Mar 12, 2019 | Press Releases

MARCH 12, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of...

bioAffinity Technologies Selected as Finalist for Cancer Innovation Award

by Maria Zannes | Mar 6, 2019 | Press Releases

MARCH 6, 2019 (San Antonio, TX) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation...

bioAffinity named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology

by Maria Zannes | Mar 6, 2019 | News

BioAffinity Technologies is proud to be named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology. Lyfebulb-Helsinn Innovation Summit March 18 and 19, 2019 Monaco,  Principality of Monaco Ten finalists will compete at the second annual...

bioAffinity Technologies Announces Award of Canadian Patent

by Maria Zannes | Feb 5, 2019 | Press Releases

FEBRUARY 4, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early...
Next Entries »

Categories

  • Articles (28)
  • Events (38)
  • News (53)
  • Press Releases (139)
  • Publications (17)

Recent Posts

  • bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 September 17, 2025
  • Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules September 9, 2025
  • U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA September 3, 2025
  • New Test Shows Promise for Improving Lung Cancer Detection, Reducing Costs for VA – US Medicine, the Voice of Federal Medicine August 29, 2025
  • bioAffinity Technologies Appoints New Members to Board of Directors August 18, 2025
CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.